What causes male pattern hair loss?

Male pattern hair loss (androgenetic alopecia) is caused by the action of dihydrotestosterone (DHT) on genetically susceptible hair follicles. DHT is produced from testosterone by the enzyme 5α-reductase (primarily type II in the scalp) and binds to androgen receptors in the dermal papilla cells of hair follicles. In follicles with inherited androgen receptor hypersensitivity — determined by the AR gene on the X chromosome — DHT binding triggers the progressive miniaturisation of the follicle: each successive hair cycle produces a shorter, thinner hair, until eventually the follicle produces only a tiny, invisible vellus hair, and then ceases production entirely. The process is gradual, predictable, and follows the Norwood-Hamilton scale of recession patterns.

Is male pattern hair loss inherited from the mother's side?

The androgen receptor (AR) gene — which determines follicle sensitivity to DHT — is located on the X chromosome, which men inherit exclusively from their mother. This is the biological basis for the traditional belief that male baldness is inherited from the maternal grandfather. However, the genetics of androgenetic alopecia are polygenic — multiple genes on multiple chromosomes (including the 20p11 locus on chromosome 20, which has no X-linkage) contribute to susceptibility. A man with a bald maternal grandfather and bald father has the highest risk. A man with neither has a significantly lower, but not zero, risk. Genetics determines susceptibility; DHT determines the rate and extent of expression.

Can androgenetic alopecia be reversed naturally?

Partial reversal — regrowth of miniaturised but not yet completely dead follicles — is possible with appropriate natural and biotech interventions, but requires realistic expectations. The window for reversal narrows as follicle miniaturisation progresses: follicles in early miniaturisation (Norwood I–III) are significantly more responsive than late-stage miniaturised follicles (Norwood V–VII). Natural 5α-reductase inhibitors (saw palmetto, Bhringraj, Methi, green tea EGCG) reduce the DHT signal to the follicle; biotech actives (Redensyl, Procapil) directly stimulate follicle stem cells and extend anagen duration. The clinical evidence for these approaches is for slowing progression and supporting partial regrowth in early-to-moderate stages — not for complete reversal of established baldness. Early intervention produces the best outcomes; the most common mistake is starting treatment at Norwood V and expecting Norwood I results.

How long does it take to see results from hair loss treatment?

The minimum timeline for any hair loss treatment is set by the hair cycle biology. Even if a treatment immediately stops DHT-driven miniaturisation, the follicles that were in telogen (resting) phase continue shedding for 3–6 months while existing anagen follicles produce new hairs. Results timelines by approach: Finasteride — measurable improvement at 6–12 months; full benefit assessment at 24 months. Minoxidil — initial shedding increase at weeks 4–8 (sign of reactivation); regrowth visible at 4–6 months; full assessment at 12 months. Redensyl/Procapil serums — slowing of shedding at 3–4 months; visible improvement at 6–9 months. Natural DHT blockers (saw palmetto, Bhringraj) — measurable effect on DHT suppression within 4–6 weeks; hair cycle response requires 3–6 months. Combination approaches (topical biotech + natural DHT blockers) are more effective than any single approach and produce results earlier in the recovery phase.

Does stress cause male pattern hair loss?

Stress does not directly cause androgenetic alopecia — but it significantly accelerates it in men who are genetically susceptible. Chronic psychological stress elevates cortisol, which impairs the hypothalamic-pituitary-gonadal axis and can increase adrenal androgen production (DHEA-S), raising the substrate available for conversion to testosterone and subsequently to DHT. Stress also drives telogen effluvium (sudden diffuse shedding) through a separate mechanism — cortisol shortens the anagen phase across all follicles, causing a mass entry into telogen. In a man with early androgenetic alopecia, a major stress event can produce a dramatic apparent worsening — a combination of stress-driven telogen effluvium on top of the underlying, slower androgenetic process. When the stress resolves, the telogen effluvium recovers; the androgenetic component does not recover without appropriate treatment.

The Botani Bestie Journal

Hair Fall in Men — Androgenetic Alopecia, DHT, and the Ayurvedic + Biotech Approach (2025)

Q: Does finasteride stop hair loss permanently?

Finasteride (1 mg/day) is the most effective pharmacological treatment for male pattern hair loss — blocking 5α-reductase type II, reducing scalp DHT by approximately 70%, and producing measurable regrowth in 65–80% of men at 2 years. However, it is not permanent: the treatment must be continued indefinitely. Stopping finasteride causes DHT levels to recover to baseline within 2–4 weeks, and hair that was maintained or regrown by DHT suppression is typically lost within 6–12 months of stopping. Additionally, finasteride carries a documented risk of sexual side effects (decreased libido, erectile dysfunction) in approximately 1.5–3.8% of users, with a smaller percentage (post-finasteride syndrome) reporting persistent side effects after discontinuation. This side effect profile is the primary reason many men seek alternatives, including the Ayurvedic + biotech topical approach.

Male pattern hair loss affects approximately 50% of Indian men by age 50 and up to 80% by age 70 — making it the most common hair condition in existence. The mechanism is well understood: DHT, the androgen receptor, and a follicle miniaturisation cascade that is gradual, predictable, and — in its early stages — interruptible. This guide covers the complete biology, the honest treatment evidence (including the side effects that manufacturers understate), and the Ayurvedic + biotech combination approach that is changing how men approach hair loss without prescription drugs.

Indian man in his 30s showing bitemporal recession and crown thinning of early androgenetic alopecia Norwood II-III

The most important thing to understand about male pattern hair loss is also the most often misrepresented: it is not a disease of the scalp. The scalp is normal. The follicles are normal. The DHT is normal. What is different — and what is entirely genetic — is the sensitivity of certain follicles' androgen receptors to DHT.

This distinction matters because it explains why no topical ingredient can 'cure' androgenetic alopecia (AGA), why the same DHT level that maintains a full beard causes crown thinning, and why treatments must address either the DHT signal or the follicle's response to it — not the scalp surface.

It also explains why early intervention is the defining variable in outcomes. A follicle that has been miniaturising for 2 years is far more recoverable than one that has been miniaturising for 10. The biology is clear: act early, use the right approach, and the trajectory can be meaningfully altered. Wait for visible baldness, and the window narrows dramatically.

⚡ Androgenetic Alopecia — Quick Reference

Cause	DHT (dihydrotestosterone) acting on androgen-receptor-sensitive follicles in the crown and temples; follicles in the occipital region are DHT-resistant
Enzyme responsible	5α-reductase type II (primary in scalp) — converts testosterone → DHT
Genetics	Polygenic; AR gene on X chromosome (from mother) is primary determinant; 20p11 locus on chromosome 20 also significant
Pattern	Bitemporal recession + crown thinning; classified by Norwood-Hamilton scale (I–VII)
Gold standard medical treatment	Finasteride 1 mg/day (oral, 5α-R II inhibitor) + Minoxidil 5% topical (vasodilator, K⁺ channel opener)
Natural 5α-R inhibitors	Saw palmetto (β-sitosterol), Bhringraj (ecliptasaponins), Methi (diosgenin), Green Tea EGCG, Pumpkin seed oil
Biotech topical actives	Redensyl (DHQG + EGCG), Procapil (biotinyl-GHK + apigenin + GABA), Anagain (pea sprout IGF-1 pathway)
Best stage to treat	Norwood I–III — early intervention produces the most meaningful response; Norwood V–VII has limited reversal potential

The DHT Mechanism — How Androgenetic Alopecia Actually Works

Male pattern hair loss is not caused by too much DHT. Men with AGA have normal circulating DHT levels — identical to men who retain a full head of hair into their seventies. What is different is the sensitivity of specific follicles' androgen receptors to DHT's signal.

testosterone to DHT, androgen receptor binding, TGF-β1 and anagen shortening

The Miniaturisation Cascade — Step by Step

5α-Reductase converts testosterone to DHT: In the scalp's dermal papilla cells, the enzyme 5α-reductase type II (5α-R II) converts circulating testosterone into DHT — a more potent androgen with approximately 5x higher androgen receptor (AR) affinity. 5α-R II is expressed at particularly high levels in the scalp's front, top, and crown regions — explaining the topographic pattern of AGA.
DHT binds the androgen receptor: In genetically susceptible follicles, the androgen receptor has an inherited hypersensitivity — it binds DHT more avidly and produces a more pronounced downstream response. The AR gene is located on the X chromosome, determining baseline AR sensitivity from birth.
DHT–AR complex upregulates TGF-β1: Inside the dermal papilla nucleus, the DHT–AR complex upregulates transforming growth factor beta-1 (TGF-β1) — a potent inhibitor of follicle growth that suppresses keratinocyte proliferation in the hair matrix and accelerates catagen (regression) entry.
Progressive shortening of anagen: Each successive hair cycle, TGF-β1 shortens the anagen duration. A follicle that originally had a 4–6 year anagen phase produces progressively shorter cycles — 3 years, then 2, then 1 year — producing shorter, finer hair with each cycle until the anagen phase is too short to produce a visible hair.
Miniaturisation to vellus: The terminal follicle (producing pigmented, thick hair) gradually converts to an intermediate follicle, then a vellus follicle (producing the colourless, near-invisible 'peach fuzz'), and eventually becomes dormant. This process spans years to decades — which is exactly the window during which treatment can alter the trajectory.

Why the Crown and Temples — but Not the Sides and Back?

The follicles in the occipital region (back and sides of the scalp) express significantly lower levels of 5α-R II and have fewer androgen receptors than crown and temple follicles — meaning they produce less DHT locally and are less responsive to its signal. This is why occipital donor hair from men with even advanced AGA retains its DHT resistance when transplanted to the crown — it is follicle-intrinsic, not location-dependent. The same biology explains why hair transplantation works: transplanted occipital follicles continue to resist DHT in their new location.

The Norwood-Hamilton Scale — Staging Your Hair Loss

Understanding your current Norwood stage is essential for realistic treatment expectations. The scale runs from I (no significant recession) to VII (only a horseshoe of hair remaining at the sides and back):

Stage	Pattern	Treatment Response	Recommended Approach
I	No significant recession; normal juvenile hairline	Prevention focus — follicles fully intact	DHT-blocking topicals, scalp health maintenance; no urgent medical treatment needed
II	Slight temple recession, hairline slightly elevated	Excellent — miniaturisation just beginning	Natural DHT blockers + biotech serum; strong response expected
III	Deep temple recession; crown may show earliest thinning	Very Good — significant reversal possible	Biotech serum + natural DHT blockers; consider finasteride/minoxidil discussion with dermatologist
IV	Significant crown thinning; temple areas meeting crown loss	Moderate — partial regrowth achievable	Medical treatment (finasteride + minoxidil) most effective; biotech topicals as adjunct
V	Crown and temple loss connecting; only a thin band separating	Limited — slowing progression primary goal	Medical treatment + topicals; hair transplant consultation reasonable at this stage
VI–VII	Extensive loss; horseshoe pattern remaining	Minimal reversal potential — many follicles permanently dormant	Hair transplant is the primary restorative option; medical/topical treatment preserves remaining hair

⚠ The Most Common Mistake in AGA Treatment: Most men seek treatment at Norwood IV–V, when visible thinning is undeniable — but follicle miniaturisation began years earlier. The ideal treatment window is Norwood I–III, when the vast majority of follicles are still present and reversible. If you have a family history of male pattern hair loss, the single best strategy is to begin treatment at the first sign of temple recession — not after crown thinning is established.

The Honest Treatment Review — What Works, What Doesn't, and the Side Effects

How it works: Finasteride 1 mg/day selectively inhibits 5α-reductase type II — the isoform responsible for the majority of scalp DHT production. This reduces scalp DHT by approximately 60–70%, significantly reducing the miniaturisation signal to androgen-sensitive follicles. In clinical trials (the landmark 2-year PLESS trial and subsequent studies), finasteride produced visible hair count improvement in 65–80% of men, with stabilisation in nearly all others.

The honest side effect picture: The package insert lists sexual side effects (decreased libido, erectile dysfunction, reduced ejaculate volume) occurring in approximately 1.8–3.8% of users during treatment. What the prescribing information underemphasises: a subset of users (estimated at 1–2%) reports persistent sexual dysfunction after stopping finasteride — termed 'post-finasteride syndrome' — including persistent erectile dysfunction, loss of libido, depression, and cognitive symptoms that can last months to years post-cessation. This is the primary reason many men — especially younger men prioritising sexual function — seek non-prescription alternatives.

Practical point: Finasteride requires indefinite use; stopping results in return of DHT levels within 2–4 weeks and subsequent hair loss within 6–12 months. Dutasteride (which blocks both 5α-R I and II, reducing scalp DHT by ~90%) is more potent but has the same side effect profile and is used off-label for hair loss in India.

How it works: Minoxidil (topical 5% solution or foam, or oral 0.25–1.25 mg off-label) was originally an antihypertensive drug — its hair growth effect was discovered as an unexpected side effect. The mechanism: minoxidil sulphate (the active metabolite, requiring conversion by the scalp enzyme SULT1A1) opens potassium channels in dermal papilla cells, increasing scalp microcirculation, extending the anagen phase, and enlarging miniaturised follicles. Critically, minoxidil does not block DHT — it does not address the androgenetic cause, only the follicle's functional response to it.

The initial shedding trap: 40–60% of men experience a significant initial shedding increase in weeks 4–8 after starting minoxidil — because it forces resting telogen follicles into anagen, pushing out existing telogen hairs simultaneously. This causes many men to stop treatment precisely when it is beginning to work. Shedding resolves by months 2–3; the key message is to continue treatment through the shedding phase.

Limitations: Minoxidil requires indefinite use — stopping causes return of hair loss within 6–12 months. Contact dermatitis from propylene glycol in the solution is common (10–15%); the foam formulation reduces this. Oral minoxidil is increasingly used in India at low doses (0.25–0.5 mg/day), producing results comparable to topical but with potential systemic effects including hypertrichosis (body hair growth) and rarely cardiac effects at higher doses — requires medical supervision.

What it is: Redensyl is a patented complex of two molecules: DHQG (dihydroquercetin glucoside — a plant-derived polyphenol) and EGCG (epigallocatechin gallate from green tea), combined with glycine and zinc. It was developed as a direct alternative to minoxidil, with a completely different mechanism.

The mechanism: DHQG specifically activates hair follicle stem cells (ORS stem cells — outer root sheath stem cells, also called hair germ cells) by targeting the DP-1 protein expressed in these cells. Activated stem cells differentiate into new hair matrix cells, directly extending and strengthening the anagen phase. EGCG provides anti-DHT activity by inhibiting 5α-reductase and anti-inflammatory support to the follicle microenvironment. The combination addresses both the growth phase and the androgenetic signal.

Clinical evidence: A 2014 published clinical trial compared Redensyl (3%) applied to the scalp against a 3% minoxidil solution. At 84 days: Redensyl increased the anagen-to-telogen ratio by 214% vs. minoxidil's 214% — essentially equivalent efficacy, but without minoxidil's initial shedding, dependency requirement, or propylene glycol irritation. Redensyl does not require indefinite use to prevent rebound loss; it acts on the follicle's own biology rather than masking androgenetic vulnerability.

What it is: Procapil is a patented combination of three actives: biotinyl-GHK (biotin coupled to a collagen-stimulating tripeptide), apigenin (a flavonoid from chamomile), and oleanolic acid (from olive leaf). Each targets a different aspect of androgenetic follicle deterioration.

Three-way mechanism:

Biotinyl-GHK: Stimulates the anchoring proteins in the dermal sheath that attach the follicle to the scalp matrix. In AGA, the follicle-scalp anchoring weakens progressively — contributing to the ease with which miniaturised hairs shed. Biotinyl-GHK counters this loss of anchoring.
Apigenin: Improves scalp microcirculation by activating local nitric oxide synthase — increasing blood flow and nutrient delivery to the dermal papilla. Also documented as a mild 5α-reductase inhibitor through flavonoid-mediated enzyme binding.
Oleanolic acid: Direct 5α-reductase inhibitor — reduces local DHT production at the follicle level without systemic hormone disruption, avoiding finasteride's systemic side effects.

Clinical evidence: Procapil clinical studies show a 121% increase in anagen hairs and a 46% reduction in hair loss at 4 months. The combination of local DHT inhibition (oleanolic acid + apigenin), improved scalp microcirculation (apigenin), and follicle anchoring (biotinyl-GHK) addresses three of the four key mechanisms of androgenetic alopecia simultaneously.

What it is: Anagain is a standardised extract of organic pea sprout (Pisum sativum var. Bikini) that acts through the IGF-1 (insulin-like growth factor 1) signalling pathway — one of the key anagen-promotion pathways in the dermal papilla that is suppressed by DHT in AGA. Anagain upregulates the expression of genes encoding IGF-1, FGF7 (fibroblast growth factor 7), and the hair keratin associated proteins (KAPs) that strengthen the hair shaft. Clinical data: a 2-month study showed a 78% improvement in the anagen-to-telogen ratio in men using Anagain-containing products. As a standalone active, Anagain is less potent than Redensyl or Procapil — but as a third active in combination, it adds the IGF-1 pathway that the other two do not specifically target, creating a synergistic multi-pathway approach.

Ayurvedic 5α-Reductase Inhibitors — The Natural DHT Blockers

Several Ayurvedic herbs contain compounds with documented 5α-reductase inhibitory activity — providing a natural DHT-blocking mechanism that complements the biotech actives' anagen-stimulation approach.

Saw Palmetto (Serenoa repens) — The Best-Evidenced Natural 5α-R Inhibitor

The fatty acid and phytosterol content of saw palmetto (principally β-sitosterol and lauric acid) inhibits both 5α-reductase type I and type II through non-competitive binding — a different binding mechanism from finasteride, making it complementary rather than redundant. A 2012 randomised trial in International Journal of Immunopathology and Pharmacology compared saw palmetto extract to finasteride in men with AGA: at 24 months, finasteride showed 68% improvement vs. saw palmetto's 38% — but saw palmetto produced no sexual side effects vs. finasteride's 1.8% rate. For men who cannot or will not take finasteride, saw palmetto is the strongest natural alternative and is available in oral supplemental form (320 mg/day standardised extract) or in topical formulations.

Bhringraj (Eclipta prostrata) — The Ayurvedic Standard

Bhringraj contains wedelolactone, ecliptasaponins, and polyacetylenes — compounds that demonstrate 5α-reductase inhibitory activity in in vitro studies. A 2009 study in Journal of Ethnopharmacology found Bhringraj extract promoted hair follicle growth in animal models comparable to 2% minoxidil. The proposed mechanism combines 5α-R inhibition with prostaglandin D2 suppression (PGD2 is the principal androgen-independent hair loss mediator discovered in 2012) and direct dermal papilla cell proliferation stimulation. Bhringraj oil applied 2–3x weekly provides both DHT reduction and follicle stimulation — making it the most appropriate Ayurvedic oil for AGA specifically.

Green Tea EGCG — The Dual-Action Active

EGCG (epigallocatechin gallate) inhibits 5α-reductase type I (the isoform that produces DHT in the sebaceous gland and skin) and independently promotes dermal papilla cell proliferation through the IGF-1 pathway. A 2007 study in Phytomedicine confirmed EGCG's 5α-R inhibitory activity at physiologically relevant concentrations. Because it targets the type I isoform rather than type II (finasteride's target), EGCG is a complementary DHT blocker — reducing scalp sebum DHT production that finasteride and saw palmetto do not optimally address. EGCG is present in both topical formulations and oral green tea supplementation (400–800 mg EGCG/day from green tea extract).

Methi / Fenugreek (Trigonella foenum-graecum) — Androgen Modulation

Methi seeds contain diosgenin — a steroidal saponin that modulates androgen receptor sensitivity through a mechanism independent of 5α-reductase inhibition. By competitively interacting with the androgen receptor, diosgenin reduces the downstream transcriptional response to DHT without reducing DHT levels. A 2016 randomised clinical study (International Journal of Medical Sciences) found fenugreek seed extract supplementation significantly reduced hair fall and increased hair growth in men over 6 months, compared to placebo. The additional benefit: fenugreek improves scalp microcirculation through its niacin content and has direct anti-inflammatory properties that reduce the scalp inflammatory infiltrate around miniaturising follicles.

The Ayurvedic + Biotech Combination — The Complete Protocol

The most effective non-prescription approach to androgenetic alopecia addresses all four key mechanisms simultaneously: DHT production reduction, androgen receptor modulation, follicle stem cell activation, and scalp microcirculation improvement. No single ingredient covers all four; the combination approach does.

Mechanism	Target	Ingredient(s)	Application
5α-Reductase inhibition	Reduce local DHT production in scalp follicles	Saw palmetto, Bhringraj, EGCG (green tea), oleanolic acid (Procapil), pumpkin seed oil	Oral + topical combined is more effective than either alone
Androgen receptor modulation	Reduce follicle sensitivity to DHT signal	Methi (diosgenin), zinc (5α-R co-inhibitor), nettle root extract	Primarily oral supplementation
Follicle stem cell activation	Re-enter miniaturised follicles into anagen from bulge ORS stem cells	Redensyl (DHQG + EGCG), Anagain (pea sprout IGF-1)	Daily scalp serum
Follicle anchoring + microcirculation	Prevent premature shedding of miniaturised hairs; improve nutrient delivery	Procapil (biotinyl-GHK + apigenin), Bhringraj oil, scalp massage	Daily serum + 2–3x weekly oil massage
Anti-inflammatory scalp environment	Reduce perifollicular inflammation that accelerates miniaturisation	EGCG, Bhringraj, neem, salicylic acid (in shampoo), jatamansi	Shampoo + oil

💡 Not sure what stage your hair loss is at, or which approach is right for your pattern? Our dermatologist assesses your specific situation and recommends the most appropriate protocol.

Book Free Hair Consultation →

The Botani Bestie Approach to Men's Hair Loss

Our hair loss products are formulated around the multi-mechanism combination approach — delivering Ayurvedic DHT-blocking actives alongside biotech follicle-stimulating compounds in formats appropriate for daily and weekly use.

Total Revival Hair Serum

Daily Scalp Serum — AM or PM

The cornerstone of the biotech approach: Redensyl (DHQG + EGCG — follicle stem cell activation, documented clinical equivalence to minoxidil at 3% with no rebound dependency), Procapil (local DHT inhibition via oleanolic acid + scalp microcirculation via apigenin + follicle anchoring via biotinyl-GHK), and Anagain (IGF-1 pathway activation in dermal papilla). Apply daily to dry scalp using the dropper; focus on the crown and temples. The combination targets three mechanisms simultaneously — making it the most complete topical approach to AGA without requiring a prescription.

Shop Total Revival Hair Serum →

Total Restore Hair Oil

Scalp Oil — 2–3x weekly

Bhringraj oil (wedelolactone and ecliptasaponins — 5α-reductase inhibition + direct follicle growth stimulation), Amla (EGCG and emblicanins — additional 5α-R inhibition + the highest natural Vitamin C for antioxidant scalp protection), Brahmi, Jatamansi, and Green Tea in a base of Redensyl and Anagain. The Ayurvedic-biotech oil for AGA: the herb-rich base reduces DHT at the scalp level while biotech actives in the carrier provide complementary anagen stimulation. Massage into the scalp 2–3x per week and leave for minimum 30 minutes before washing. Scalp massage alone has documented DHT-reduction potential (increased scalp blood flow → reduced local androgen concentration).

Shop Total Restore Hair Oil →

Hair Loss Progressing Despite Treatment? Get a Targeted Assessment

Our in-house dermatologist assesses your Norwood stage, family history, lifestyle factors, and any co-existing conditions (thyroid, nutritional deficiency) that may be accelerating your AGA. The prescription approach, the natural approach, or the combination — a personalised protocol is the most effective way forward. No purchase required.

Book Free Consultation → WhatsApp Us

Frequently Asked Questions

Male pattern hair loss (androgenetic alopecia) is caused by DHT — dihydrotestosterone — acting on genetically susceptible hair follicles in the crown and temple regions. 5α-reductase type II converts testosterone to DHT in the scalp's dermal papilla cells; DHT binds to androgen receptors that have an inherited hypersensitivity to its signal. The DHT–AR complex upregulates TGF-β1 — a potent follicle growth inhibitor — which progressively shortens the anagen (growth) phase with each successive hair cycle. Over years to decades, terminal follicles miniaturise to vellus follicles and eventually become dormant. Occipital follicles (back and sides) are resistant to this process, which is why this hair is retained and usable for transplantation.

Partially — the AR (androgen receptor) gene, located on the X chromosome inherited exclusively from the mother, is the primary genetic determinant of follicle DHT sensitivity. This is the biological basis for the traditional belief that baldness is inherited from the maternal grandfather. However, AGA is polygenic: a significant susceptibility locus on chromosome 20 (20p11) has no X-linkage, meaning paternal family history also contributes meaningfully. A man with a bald maternal grandfather has elevated risk; a man with a bald maternal grandfather and a bald father has the highest risk. Genetics determines susceptibility; DHT levels and age determine the rate and extent of expression.

No — finasteride requires indefinite use. It suppresses scalp DHT by ~70% while being taken; stopping treatment allows DHT to recover to baseline within 2–4 weeks, and hair maintained or regrown by DHT suppression is typically lost within 6–12 months. Finasteride is effective — 65–80% of men see improvement at 2 years — but it is a treatment, not a cure. The documented risk of persistent sexual side effects (post-finasteride syndrome) in a subset of users is the primary reason many men seek alternatives. Natural DHT blockers (saw palmetto 320 mg/day, Bhringraj topical) and biotech actives (Redensyl, Procapil) provide an evidence-supported alternative for men who prefer to avoid prescription medication, with lower efficacy than finasteride but without its systemic hormonal disruption.

Partial reversal is possible — but only in follicles that are miniaturised, not permanently dormant. The best outcomes occur at Norwood I–III, when the majority of follicles still have viable stem cells in the bulge region. At these stages, natural DHT blockers (saw palmetto, Bhringraj, EGCG) combined with biotech actives (Redensyl, Procapil, Anagain) can meaningfully slow progression and produce regrowth of fine, miniaturised hairs. At Norwood V–VII, follicles in the affected areas are largely dormant; the natural/biotech approach can preserve remaining hair but reversal potential is limited. Early intervention is the defining variable — starting treatment 2–3 years into the miniaturisation process produces significantly better outcomes than starting 10 years in.

The minimum timeline is set by the hair cycle. Even with an immediately effective DHT reduction, follicles in telogen continue shedding for 3–6 months before new anagen hairs emerge. For biotech topicals (Redensyl, Procapil serum): reduced shedding at 3–4 months; visible new growth at 6–9 months; full assessment at 12 months. For finasteride: measurable improvement at 6–12 months; full benefit at 24 months. For natural DHT blockers: measurable effect on DHT within 4–6 weeks; hair cycle response at 3–6 months. All approaches: shedding may temporarily increase in the first 4–8 weeks as reactivated follicles displace existing telogen hairs — this is a positive sign. The most common mistake is stopping treatment at 8 weeks because of apparent worsening, when that worsening actually indicates the treatment is working.

Stress does not directly cause androgenetic alopecia — but significantly accelerates it in genetically susceptible men. Chronic stress elevates cortisol, which impairs the HPG axis and increases adrenal androgen production, raising DHT substrate availability. Acute psychological stress drives simultaneous telogen effluvium (mass diffuse shedding within 2–3 months of the stress event) on top of the underlying androgenetic process — causing apparent dramatic worsening. When the acute stress resolves, the telogen effluvium reverses within 6 months; the androgenetic component does not. Men who notice sudden, dramatic worsening after a major life stressor (illness, bereavement, job loss, major surgery) should investigate both stress-related and androgenetic causes, as both are typically active simultaneously.

Indian man with restored hairline density after 12 months of DHT-blocking and biotech serum treatment

The Bottom Line: Act Early, Target DHT, and Use the Right Combination

Androgenetic alopecia is the most common hair condition in the world — but it is also one of the most treatable when approached at the right stage with the right tools. The DHT mechanism is well understood; the treatments that interrupt it are well evidenced; and the window for meaningful reversal is wider than most men realise — if they act before significant miniaturisation has occurred.

The choice between the prescription approach (finasteride + minoxidil — most potent, requires indefinite use, carries side effect risk) and the Ayurvedic + biotech approach (saw palmetto + Bhringraj + Redensyl + Procapil — less potent but no systemic side effects, no dependency) is a personal decision that should be made with complete information. Both are legitimate; neither is without trade-offs.

What is not a legitimate choice: doing nothing while the follicles miniaturise past the point of return. The biology is clear — the follicle can recover from miniaturisation; it cannot recover from complete dormancy.

Shop Total Revival Hair Serum → Free Hair Consultation